OpenEvidence High-CPM Clinician Ads

This reveals that OpenEvidence has built one of the rarest ad businesses in software, a product that reaches doctors exactly when they are deciding what to read, prescribe, or use. Because the audience is licensed clinicians in a clinical workflow, each impression can be worth far more than a normal social ad, which lets the company stay free, keep adoption friction low, and still monetize heavily without filling the product with ads.1 2 3 4

• The core mechanic is intent. A pharma or device company is not buying broad awareness, it is buying access to a doctor actively researching a case. That is much closer to search advertising than brand advertising, which explains why OpenEvidence can command $70 to $150+ CPMs in earlier research and four figure CPMs on the highest value inventory later.1 2 3
• Selling only about 5% of inventory means demand is stronger than supply, not weaker. With roughly 20 million monthly consultations by January 2026 and 1 million consultations in a single day by March 10, 2026, OpenEvidence can be selective about where ads appear, preserve product trust, and still scale revenue as usage grows.2 4
• This model is the mirror image of incumbents like UpToDate. UpToDate sells subscriptions to hospitals and clinicians, launched Expert AI in October 2025, and emphasizes an enterprise, non ads funded workflow. OpenEvidence instead uses free access to skip hospital procurement and then monetizes the attention that free distribution creates.2 4 5

Going forward, the upside comes from widening the doctor workflow while keeping ad load scarce. As OpenEvidence adds notes, calling, billing, and prescribing around search, each session becomes more commercially valuable, which should let revenue compound faster than usage and push the market toward a split between free ads funded tools and paid enterprise clinical software.2 4 5